Dyax Corp. has received FDA approval of DX-88 in hereditary angioedemia (HAE). DX-88 is a recombinant, small protein manufactured in yeast (P. pastoris). The drug, which will be marketed as Kalbitor, offers a new treatment option for treating acute attacks of HAE, a debilitating disease which causes severe, often painful swelling affecting the extremities (hands, feet, face, etc.), the gastrointestinal tract, the genitalia and, in potentially life-threatening cases, the larynx. Dyax has w...